 | | Anno V – Numero 62, Dicembre 2023 | Comitato scientifico editoriale: Vanna Chiarion Sileni, Paola Queirolo
Editore: Intermedia, Direttore Responsabile: Mauro Boldrini | | |
Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy
Background: Targeted therapy (TT) of BRAF V600 mutated unresectable melanoma with inhibitors of the MAPK pathway achieves response rates of up to 76%, but most patients develop secondary resistance. Albeit TT is strikingly efficacious during the first days of treatment, even in advanced cases, long-term survival is highly unlikely, especially in patients with unfavorable baseline characteristics like elevated lactate dehydrogenase (LDH). In patients … Continua a leggere
|
A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM)
Background: BRAF+MEK inhibitors extend life expectancy of patients with BRAFV600 mutant advanced melanoma. Acquired resistance limits duration of benefit, but preclinical and case studies suggest intermittent dosing could overcome this limitation. INTERIM was a phase 2 trial evaluating an intermittent dosing regimen. Methods: Patients with BRAFV600 … Continua a leggere
Outcomes in patients with BRAFV600-mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinib
Background: Brain metastases (BM) and lactate dehydrogenase (LDH) levels above the upper limit of normal (ULN) are associated with poor prognosis in patients with melanoma. Although treatment with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib have demonstrated long-term clinical benefit in patients with melanoma, data on their efficacy in patients with BM are limited … Continua a leggere
The features and management of acquired resistance to PD1-based therapy in metastatic melanoma
Background: Anti-PD-1 therapy (PD1) either alone or with anti-CTLA-4 (CTLA4), has high initial response rates, however 20% of patients (pts) with complete response (CR) and 30% with partial response (PR) within 12 months of treatment experience subsequent disease progression by 6 years. The nature and optimal management of this acquired resistance (AR) remains unknown … Continua a leggere
Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma
Background: The outcome of patients with resectable mucosal melanoma is poor. Toripalimab combined with axitinib has shown impressive results in metastatic mucosal melanoma with an objective response rate of 48.3% and a median progression-free survival of 7.5 months in a phase Ib trial. It was hypothesized that this combination administered in the neoadjuvant setting might induce a pathologic response in resectable mucosal melanoma, so we … Continua a leggere
|
Lo sviluppo dell’assistenza oncologica: nuovi bisogni e nuove risposte
Cuneo, 21 dicembre 2023
Making Palliative Care a part of your Oncology Practice
I mercoledì dell’oncologia
Webinar , 10 gennaio 2024 dalle 17.00 alle 18.15
Corso per Quality Assurance e Auditor
FAD , 11 gennaio – 18 marzo 2024
Back from San Antonio 2024
Genova, 12 – 13 gennaio 2024
Quali le sfide da affrontare nel Tumore Germinale del testicolo
I mercoledì dell’oncologia
Webinar , 17 gennaio 2024 dalle 17.00 alle 18.15
Best from San Antonio 2023
Webinar ECM, 25 gennaio 2024
La Ricerca alla Portata del Paziente 3.0
Roma, 26 gennaio 2024
SCUOLA DI METODOLOGIA DELLA RICERCA CLINICA 2024
Negrar (VR), 26 – 27 gennaio 2024
| Questi e altri appuntamenti si possono consultare sul sito AIOM: www.aiom.it
|
| |
© 2023 Editore: Intermedia srl Via Lunga 16a Brescia, BS 25124 Italy
tel. 030 226105 – 388 8896214 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001
Iscrizione al Registro degli Operatori di Comunicazione N. 4867
Per contattare la redazione e commentare le notizie clicca qui
Per consultare i numeri arretrati della newsletter clicca qui
Ricevi questa email perché sei iscritto alla newsletter AIOM Cancellati
Privacy
“Si ringrazia Pierre Fabre Pharma s.r.l. per il supporto incondizionato”
|
|
|
|
|